Metoclopramide Accord (Metoclopramide Hydrochloride)

Metoclopramide exerts its effect by competitively antagonizing dopamine D2 receptors in the chemoreceptor trigger zone of the brain, reducing the sensation of nausea. It also blocks 5‑HT3 receptors and stimulates cholinergic pathways, which together promote faster gastric emptying and improve upper‑GI tract motility.

The appropriate dose of Metoclopramide Accord is determined by the prescribing clinician based on the patient’s condition, age, renal function, and response to therapy. Dosage regimens vary, and the prescriber will provide specific instructions tailored to each individual case.

Safety data for Metoclopramide Accord in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after a careful risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metoclopramide differs from many antiemetics by combining dopamine D2 antagonism with prokinetic activity, which can be advantageous for patients with delayed gastric emptying. Other agents, such as ondansetron, act primarily on serotonin receptors and lack the gastric motility‑enhancing effect, making metoclopramide a preferred choice when both anti‑nausea and prokinetic actions are needed.

Metoclopramide Accord should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metoclopramide Accord is administered orally, typically as a tablet taken with or without food as directed by the prescriber. The exact timing and frequency depend on the individual’s therapeutic needs and the clinician’s instructions.

Serious risks include extrapyramidal symptoms such as dystonia or tardive dyskinesia, neuroleptic malignant syndrome, and severe depression. Patients should be monitored for any abnormal movements, mood changes, or signs of muscle rigidity, and the medication should be discontinued promptly if these events occur.

Metoclopramide Accord is contraindicated in individuals with known hypersensitivity to metoclopramide, those with a history of seizure disorders, and patients taking monoamine oxidase inhibitors. Caution is also advised for patients with severe renal impairment, and it should be avoided in children under 18 years for long‑term use.